Evidence map›Paper›PMID 39636517›Full record

ArticleIrish journal of medical science2025

Nintedanib and its combination with immunosuppressives in connective tissue disease-related interstitial lung diseases.

Emre Tekgoz, Seda Yurumez Colak, Ezgi Cimen Gunes, Nesrin Ocal, Muhammet Cinar, Sedat Yilmaz

Abstract read
PubMed Publisher
In one paragraph

Article in Irish journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Combination antifibrotic and immunosuppressive therapy in progressive fibrosing ILD.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Emre TekgozDivision of Rheumatology, Department of Internal Medicine, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, 06100, Turkey.ORCID http://orcid.org/0000-0002-0866-1503
Seda Yurumez ColakDivision of Rheumatology, Department of Internal Medicine, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, 06100, Turkey. sedayurumez@hotmail.com.ORCID http://orcid.org/0000-0002-5703-6739
Ezgi Cimen GunesDivision of Rheumatology, Department of Internal Medicine, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, 06100, Turkey.ORCID http://orcid.org/0000-0002-0156-011X
Nesrin OcalDepartment of Pulmonology, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey.ORCID http://orcid.org/0000-0002-3789-7769
Muhammet CinarDivision of Rheumatology, Department of Internal Medicine, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, 06100, Turkey.ORCID http://orcid.org/0000-0002-6150-3539
Sedat YilmazDivision of Rheumatology, Department of Internal Medicine, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, 06100, Turkey.ORCID http://orcid.org/0000-0002-4691-3417

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNintedanib reduces the decline of pulmonary function in patients with advancing lung fibrosis.

aimTo assess the characteristics of the patients with connective tissue diseases (CTDs) related to interstitial lung disease (ILD) under nintedanib treatment.

methodsThe CTD-related ILD patients under nintedanib treatment who were followed up between 2020 and 2023 were included in the study. The clinical data of the patients before and after nintedanib were evaluated retrospectively.

resultsThere were 36 patients (19 female) with a mean age of 65.2 ± 8.5 years who were treated with nintedanib. The median duration for nintedanib treatment was 19 months. The most common CTD was Sjogren's syndrome (36.1%), followed by systemic sclerosis (27.8%), rheumatoid arthritis (25%), undifferentiated CTD (8.3%), and inflammatory myositis (2.8%). Fifteen (41.7%) patients had impaired pulmonary function tests (FVC < 70 ml and/or DLco < 80 ml), and 23 (63.9%) patients had ≥ 20% involvement of parenchyma in high-resolution computed tomography (HRCT) before nintedanib. According to HRCT findings, 25 (69.4%) patients had the usual interstitial pneumonia pattern. All patients had 300 mg/day of nintedanib and received at least one immunosuppressive treatment during the study period. The mean %predicted value of FVC was 82.8 ± 17.6, and DLco was 65.3 ± 19.2 before nintedanib treatment. Following the 6-month follow-up, FVC showed an increase to 92.3 ± 15.8 (with an R correlation coefficient of 0.54, p = 0.025), and 22 (61.1%) patients exhibited either stabilization or regression of findings on HRCT.

conclusionsNintedanib emerges as a promising therapeutic agent compatible with immunosuppressives for treating progressive lung fibrosis in patients with CTD-related ILD.

Indexed as

Connective Tissue DiseasesImmunosuppressive AgentsIndolesLung Diseases, InterstitialAgedDrug Therapy, CombinationFemaleHumansMaleMiddle AgedRespiratory Function TestsRetrospective StudiesImmunosuppressive AgentsIndolesnintedanibConnective tissue diseaseImmunosuppressivesInterstitial lung diseaseNintedanibProgressive pulmonary fibrosis

Identifiers

PMID39636517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.